As shown in "Intra-Surgical Study of Fat Reduction In Vivo", belly fat treated by a Board-certified plastic surgeon in vivo during an abdominoplasty was immediately reduced by one-third with an 8-minute UltraSlim® treatment.
According to the surgeon, "It was mushy, with a congealed jelly type of appearance. It looked like the fat had melted, although there was no heat. Only light.”
In 2018 multi-site clinical trials (NCT02867150 at ClinicalTrials.gov), researchers documented that UltraSlim® Professional provides the results that so many of your patients want:
Immediate Results. All patients lost fat immediately -- without dieting, exercise, drugs, or surgery.
Dramatic Fat Loss At Each Visit. Patients lost an average of 1,580cc of fat in just 32 minutes (3.5" combined waist, hips, and thighs). During one visit!
Works For Everyone. Every patient had clinically significant losses at each visit, ranging from 717cc to 4,608cc (1 5/8" to 10" from the waist, hips, and thighs).
Durability. Patients seen at follow-up had lost an additional 1 1/8" of fat during the week following treatment. With UltraSlim®, patients lose the fat permanently through a natural bodily function known as "lipolysis", whereby the contents of their fat cells are excreted primarily in their waste.
In 2018 multi-site clinical trials (NCT03647748 at ClinicalTrials.gov), researchers documented that UltraSmooth™ is second only to UltraSlim® Professional for fat reduction (average losses of 3.9" 14 days post-treatment) and UltraSmooth™ also significantly improves the appearance of cellulite noninvasively.
We are currently sponsoring clinical trials (NCT04525573 at ClinicalTrials.gov) as an open-label evaluation of the effects of a red/gold/IR LED combination light on the reduction of fat. The results shall be compared to previous results from a comparator UltraSlim® device utilizing only red LED monotherapy for the non-invasive reduction in fat layer for body contouring.
We are currently sponsoring clinical trials (NCT04524715 at ClinicalTrials.gov) to determine if a reduction of pneumonic inflammation occurs after treatment with our investigational device applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.
The United States Patent and Trademark Office has also accepted our U.S. Patent Application No.: 63/074,790 for the treatment of COVID-19, and more generally a utility patent for RESPIRATORY TREATMENT DEVICE AND METHOD UTILIZING OPTICAL EMITTERS, as invented by our COO Terry "Judson"Ward II and CEO Terry J. Ward, Sr., M.H.A.
Listed below are studies demonstrating the power, penetration, and efficacy of UltraSlim®, along with blood chemistry studies which find no increase in serum triglycerides or cholesterol:
Other novel research currently includes the treatment of lymphedema by vascular surgeon Michael Romberg, MD, FACS and the treatment of surgical wounds by investigator Robert H. Burke, MD, MS, DDS, FACS, FICS.
We are currently adding sites and investigators for both on-going IRB clinical trials listed above. We are also interested in sponsoring research to validate the efficacy of our technologies for additional indications for use, including the treatment of sleep apnea, asthma, tissue healing, accelerated wound healing, depression, and certain neurological disorders.
Independent laboratory testing, bench testing, animal testing, international standards accreditations, and U.S. patents awarded for the UltraSlim® Professional and UltraSmooth™ include:
The United States Patent and Trademark Office has awarded our inventors U.S. Patents No.: 9,044,595, 9,498,641, and 9,808,314 and has accepted our pending U.S. Patent Application No.: 63/074,790 for the treatment of COVID-19 and for other respiratory treatments.
We also have patents issued or pending in 146 other countries.
The United States Patent and Trademark Office has also awarded several registered trademarks, including UltraSlim®.
Our patents, trademarks, and other intellectual property are held by Blue Water Innovations, LLC.